Search Results for: "Clinic Roundup"
-
Clinic Roundup
Cellceutix Corp., of Beverly, Mass., said that it expects to start clinical trials with its anti-cancer drug Kevetrin in about three weeks at Harvard Cancer Center's Dana-Farber Cancer Institute and the Beth Israel Deaconess Medical Center...That follows institutional review board approval of an amended trial protocol, and hospital preparations are now under way at the respective institutions to allow for the commencement of the clinical trialsBioWorld Today | Tuesday, September 25, 2012 -
Clinic Roundup
ViroPharma Inc., of Exton, Pa., and Halozyme Therapeutics Inc., of San Diego, said the FDA provided guidance enabling ViroPharma to resume clinical trials testing the subcutaneous administration of hereditary angioedema drug Cinryze (C1 esterase inhibitor [human]) in combination with Halozyme's recombinant human hyaluronidase (rHuPH20BioWorld Today | Monday, September 24, 2012 -
Clinic Roundup
Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., said it started a clinical trial testing Impracor, a topical cream designed to deliver ketoprofenBioWorld Today | Thursday, September 20, 2012 -
Clinic Roundup
Aeras, of Rockville, Md., and the Infectious Disease Research Institute (IDRI) said they started a clinical trial of IDRI's tuberculosis vaccine candidate, ID93 + GLA-SE...Pacific Therapeutics Ltd., of Vancouver, British Columbia, said it completed enrollment and initial dosing in its first clinical trial testing PTL-202 in healthy volunteersBioWorld Today | Friday, August 24, 2012 -
Clinic Roundup
If approved, the product, indicated for the treatment of autoimmune and inflammatory diseases, will enter clinical trialsBioWorld Today | Friday, August 17, 2012 -
Clinic Roundup
Immatics biotechnologies GmbH, of Tübingen, Germany, published data from two clinical trials of IMA901, a cancer vaccine candidate, showing that patients experience longer survival times when their immune system responds to more than one of the peptides in the vaccineBioWorld Today | Tuesday, July 31, 2012 -
Clinic Roundup
Infectex, of Moscow, said it received approval from the Russian Ministry of Health to begin a pivotal clinical trial for antibiotic SQ109 in multidrug-resistant tuberculosis (MDR-TB) patients at TB centers in three major Russian cities (Moscow, Saint Petersburg and EkaterinburgBioWorld Today | Friday, July 27, 2012 -
Clinic Roundup
BHR Pharma LLC, of Phoenix, said it reached its SyNAPSe clinical trial enrollment midpoint of 590 patients...ICT-121 is the second dendritic-cell-based vaccine to enter clinical trialsBioWorld Today | Thursday, July 26, 2012 -
Clinic Roundup
Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said Phase IIa ocular safety results published in the American Journal of Ophthalmology showed that CPP-109 (vigabatrin), a GABA aminotransferase inactivator in clinical trials to treat cocaine addiction, did not cause a decrease in visual acuity or significant peripheral visual field changes with short-term useBioWorld Today | Friday, June 29, 2012 -
Clinic Roundup
In addition to clearance to proceed with clinical trials, the company also received approval of the protocol from the institutional review board and scientific review committeeBioWorld Today | Wednesday, June 27, 2012 -
Clinic Roundup
Oncolytics Biotech Inc., of Calgary, Alberta, said that it entered an agreement with the NCIC Clinical Trials Group at Queen's University, Kingston, Ontario, which will sponsor and conduct a randomized Phase II study of Reolysin in patients with advanced or metastatic breast cancerBioWorld Today | Friday, June 22, 2012 -
Clinic Roundup
Bristol-Myers Squibb Co., of New York, formed a strategic partnership with Emory University in Atlanta to conduct clinical trials involving the pharma's investigational compoundsBioWorld Today | Thursday, June 21, 2012 -
Clinic Roundup
e-Therapeutics, of Oxford, UK, said that it has started a first clinical trial evaluating its ETS2101 compound as a treatment for cancerBioWorld Today | Wednesday, June 20, 2012 -
Clinic Roundup
Sinovac Biotech Ltd., of Beijing, said that it has received a positive SFDA inspection of the three clinical trial sites in China that it is using in a Phase III study of inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth diseaseBioWorld Today | Tuesday, June 12, 2012 -
Clinic Roundup
clinical trial in June testing allergy immunotherapy JRC-LAMP-Vax in subjects sensitive to Japanese red cedar pollen...Oncolytics Biotech Inc., of Calgary, Alberta, said it entered an agreement for the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, to sponsor and conduct a Phase II study of Reolysin in patients with advanced or metastatic colorectal cancerBioWorld Today | Friday, May 4, 2012 -
Clinic Roundup
In addition, the long-term safety and tolerability of the drug was consistent with that observed in clinical trials, with no new safety signals emergingBioWorld Today | Thursday, April 26, 2012 -
Clinic Roundup
The next clinical trial of the defensin-mimetic antibiotic as a single dose is planned for later this yearBioWorld Today | Tuesday, April 24, 2012 -
Clinic Roundup
Fibrocell Science Inc., of Exton, Pa., said pivotal clinical trial data demonstrated that Laviv (azficel-T) for nasolabial fold wrinkles is effectiveBioWorld Today | Thursday, April 19, 2012 -
Clinic Roundup
Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., completed enrollment of patients in a set of clinical trials to determine the usefulness of oxidation reduction potential in hospital readmission prediction, prevention and reduction in a group of patients presenting to the emergency department with chest pain...PharmAthene Inc., of Annapolis, Md., said new data based on a recent analysis of previous human clinical trial immunogenicity data and nonclinical animal study results for rPA anthraxBioWorld Today | Friday, April 13, 2012 -
Clinic Roundup
Threshold Pharmaceuticals Inc., of South San Francisco, received a $20 million milestone payment from Darmstadt, Germany-based Merck KGaA, which was triggered by results from a clinical trial of its drug TH-302 in pancreatic cancerBioWorld Today | Thursday, April 12, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.